Therapeutic drug blocks nicotine's effects on brain chemistry

November 08, 2001

Study in rats may lead to treatment for nicotine addiction in humans

UPTON, NY -- Nicotine is widely believed to trigger dependence by elevating certain brain chemicals associated with pleasure and reward. Now, a study in rats at the U.S. Department of Energy's Brookhaven National Laboratory shows that topiramate -- a new anticonvulsant drug sold under the brand name Topomax®, currently used for the treatment of epilepsy -- can block some of the nicotine-triggered changes in brain chemistry, and may have potential for the treatment of nicotine addiction in humans.

"This treatment strategy uses a drug that simultaneously targets two different neurotransmitter pathways, thereby reducing the neurochemical activity believed to underlie nicotine addiction," said Wynne Schiffer, lead author of the study. The findings appear in the December 1, 2001, issue of the journal Synapse.

Brookhaven scientists have been studying the neurochemistry of drug addiction for nearly two decades, and have used information gathered from these studies to investigate potential pharmacologic treatments for drug abuse. Previous studies focused on agents that block drug-induced increases in brain dopamine, a neurotransmitter associated with pleasure and reward.

"But new theories about nicotine dependence suggest that dopamine isn't the only system involved," said Brookhaven neuroanatomist Stephen Dewey, a coauthor on the study. For example, nicotine stimulates specific excitatory systems in the brain, and these systems excite not only dopamine but a host of other brain chemicals, such as norepinephrine and serotonin.

Schiffer, a Stony Brook University Department of Neurobiology graduate student who works with Dewey, suggested studying topiramate because it is believed to control the brain's reward pathways by two distinct mechanisms: 1) by reducing excitatory input to the dopamine system, and 2) by raising the activity of GABA, a brain chemical that inhibits dopamine.

In the current study, scientists injected one group of rats with topiramate while another group received control injections of saline. The scientists then gave both groups an acute dose of nicotine and measured dopamine, norepinephrine, and serotonin levels in their brains. Animals given topiramate but no nicotine were also studied to see if topiramate alone had any effect on the neurotransmitters. The scientists also tested the effect of topiramate on dopamine in animals that had been pretreated with nicotine for 14 days prior to the experiment, to serve as a model for humans addicted to the drug.

As expected, animals that received saline and then nicotine showed significant increases in all three brain chemicals. Rats that had been previously "addicted" to nicotine showed even greater elevations in brain dopamine than those that received just the acute dose -- similar to what you'd expect to see in a smoker who has a cigarette after a period of not smoking.

Pretreatment with topiramate, however, completely blocked nicotine-triggered increases in norepinephrine and dopamine -- and even modulated the dopamine response in the "addicted" animals. "Since the brain's dopamine and norepinephrine systems are closely linked, the ability of topiramate to reduce increases in both neurotransmitters suggests that this drug has potential for treating nicotine abuse," Schiffer said.

Topiramate did not significantly modulate the effect of nicotine on serotonin, however. In fact, serotonin was the only neurotransmitter affected by topiramate alone, showing a slight increase.

Human studies conducted elsewhere suggest that specific drugs that increase serotonin appear to diminish the incidence of smoking. From this, the researchers propose that the ability of topiramate to increase serotonin activity, while at the same time controlling dopamine and norepinephrine, might contribute to its promise as a treatment for nicotine addiction.
This work was funded by the U.S. Department of Energy, which supports basic research in a variety of scientific fields; the National Institute of Mental Health; and the National Institute on Drug Abuse.

The U.S. Department of Energy's Brookhaven National Laboratory conducts research in the physical, biomedical, and environmental sciences, as well as in energy technologies. Brookhaven also builds and operates major facilities available to university, industrial, and government scientists. The Laboratory is managed by Brookhaven Science Associates, a limited liability company founded by Stony Brook University and Battelle, a nonprofit applied science and technology organization.

Note to local editors: Wynne Schiffer lives in Sound Beach, New York; Stephen Dewey lives in Manorville, New York.

DOE/Brookhaven National Laboratory

Related Dopamine Articles from Brightsurf:

Dopamine surge reveals how even for mice, 'there's no place like home'
''There's no place like home,'' has its roots deep in the brain.

New dopamine sensors could help unlock the mysteries of brain chemistry
In 2018, Tian Lab at UC Davis Health developed dLight1, a single fluorescent protein-based biosensor.

Highly sensitive dopamine detector uses 2D materials
A supersensitive dopamine detector can help in the early diagnosis of several disorders that result in too much or too little dopamine, according to a group led by Penn State and including Rensselaer Polytechnic Institute and universities in China and Japan.

Dopamine neurons mull over your options
Researchers at the University of Tsukuba have found that dopamine neurons in the brain can represent the decision-making process when making economic choices.

Viewing dopamine receptors in their native habitat
A new study led by UT Southwestern researchers reveals the structure of the active form of one type of dopamine receptor, known as D2, embedded in a phospholipid membrane.

Significant differences exist among neurons expressing dopamine receptors
An international collaboration, which included the involvement of the research team from the Institut de Neurociències of the UAB (INC-UAB), has shown that neurons expressing dopamine D2 receptors have different molecular features and functions, depending on their anatomical localization within the striatum.

How dopamine drives brain activity
Using a specialized magnetic resonance imaging (MRI) sensor that can track dopamine levels, MIT neuroscientists have discovered how dopamine released deep within the brain influences distant brain regions.

Novelty speeds up learning thanks to dopamine activation
Brain scientists led by Sebastian Haesler (NERF, empowered by IMEC, KU Leuven and VIB) have identified a causal mechanism of how novel stimuli promote learning.

Evidence in mice that childhood asthma is influenced by the neurotransmitter dopamine
Neurons that produce the neurotransmitter dopamine communicate with T cells to enhance allergic inflammation in the lungs of young mice but not older mice, researchers report Nov.

Chronic adversity dampens dopamine production
People exposed to a lifetime of psychosocial adversity may have an impaired ability to produce the dopamine levels needed for coping with acutely stressful situations.

Read More: Dopamine News and Dopamine Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to